Highlights Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Delayed Nasdaq Other stock markets 07:49:52 17/05/2024 pm IST			5-day change	1st Jan Change
2.15 ^USD	-2.71%		-28.57%	-11.16%

13/02	Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02	CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	15/11	CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	21/23/21	CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	12/23/12	CI
Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of Aneb-001 as A Treatment for Acute Cannabinoid Intoxication	28/23/28	CI
Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions	08/23/08	PR
Anebulo Pharmaceuticals, Inc. Appoints Sandra Gardiner as Acting Chief Financial Officer	08/23/08	CI
ANEBULO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10/23/10	AQ
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	10/23/10	CI
Anebulo Pharmaceuticals, Inc. Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication	09/23/09	CI
Anebulo Pharmaceuticals : Corporate Presentation November 2022	20/22/20	PU
ANEBULO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10/22/10	AQ
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	10/22/10	CI
Anebulo Pharmaceuticals, Inc. Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication	26/22/26	CI
ANEBULO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	09/22/09	AQ
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	09/22/09	CI
Anebulo Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	09/22/09	CI
Anebulo Pharmaceuticals Announces Positive Topline Data for Aneb-001 from A Phase 2 Clinical Trial for Acute Cannabinoid Intoxication	05/22/05	CI
Anebulo Pharma Sees Topline Mid-Stage Trial Data for Acute Cannabinoid Intoxication July 5	24/22/24	MT
Anebulo Pharmaceuticals, Inc. Announces Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022	24/22/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Anebulo Pharmaceuticals, Inc.

Equities

ANEB

US0345691036

Highlights

Filters